Jump to content

A precision-instrument readout of the PT-141 (bremelanotide) literature — the approved-population evidence, the effect-size debate, and the tolerability picture read first.

Editorial desk · PT-141

Contact the PT-141 Editorial Desk

For corrections, sourcing questions, and editorial correspondence about the bremelanotide literature.

Editorial Correspondence

Use the form below to reach the editors of Medicine PT-141 about the published record on PT-141 (bremelanotide). Corrections, citation queries, and notes on studies to add are welcome — particularly anything that sharpens the accuracy of a measured value or its source.

What this desk does not do: it gives no medical advice, recommends or supplies no compound, and answers no requests to purchase, source, or price anything. Bremelanotide is a prescription drug for one approved indication; whether it is appropriate for an individual is a question for a licensed prescriber, not for a reading desk.

What to Expect

This is an editorial inbox, not a clinical or commercial one. If you write about a specific number on the site, point us to the page and the figure and we will check it against the cited source. If a citation has been updated, retracted, or annotated since publication, tell us — we treat the citation register as a living document and would rather correct the record than defend it.

We read everything and reply selectively. There is no account, no order, and no consultation attached to this form — only the editorial conversation about what the PT-141 literature actually shows.